Leiden Bio Science Park’s startup Rapidemic is advancing the next generation of diagnostics, partnering with global health organizations to improve access to crucial health services. With support from the Bill & Melinda Gates Foundation, Rapidemic is set to make significant strides in accessible diagnostics, focusing initially on sexually transmitted infections (STIs) in underserved regions. This project represents an impactful leap in women’s health worldwide.
In a new collaboration, Rapidemic joins forces with Mohammed Majam and the Ezintsha team in Johannesburg, South Africa, to develop a rapid, cost-effective molecular test for chlamydia and gonorrhea. This innovative diagnostic solution, designed for primary care settings, is aimed at providing reliable, disposable tests suited to low-resource environments. By accurately detecting both symptomatic and asymptomatic cases, the test will be a game-changer in early diagnosis and treatment, especially in remote communities.
The partnership also involves comprehensive research into user preferences, usability, and regulatory standards in South Africa, ensuring that the final product aligns with the needs of pharmacies and primary healthcare providers. Through this initiative, Rapidemic is taking a crucial step toward accessible, decentralized diagnostics that will enhance STI detection and treatment for women in hard-to-reach areas.
This collaboration is a testament to Rapidemic’s commitment to transforming health diagnostics and supporting equitable healthcare access across the globe
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.